Vaccine Effectiveness, Burden and Impact Studies (VEBIS), Vaccine effectiveness against COVID-19 and seasonal influenza among patients presenting to primary care physicians in EU/EEA

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000095
• EU PAS number:
  EUPAS1000000095
• Study ID:
  1000000095
• Official title and acronym:
  Vaccine Effectiveness, Burden and Impact Studies (VEBIS), Vaccine effectiveness against COVID-19 and seasonal influenza among patients presenting to primary care physicians in EU/EEA
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  Hungary

  Ireland

  Netherlands

  Portugal

  Romania

  Spain

  Sweden
• Study description:
  Primary care systems offer the opportunity to conduct vaccine effectiveness studies; ECDC has since 2007 commissioned annual influenza vaccine effectiveness studies against seasonal influenza in primary care settings. Since February 2022, leveraging previous efforts and experience, the VEBIS primary care network has conducted studies for the vaccine effectiveness of both seasonal influenza and COVID-19 against moderate disease.
• Study status:
  Ongoing

Research institutions and networks

Institutions

European Centre for Disease Prevention and Control

EpiConcept

Study timelines

Date when funding contract was signed

Actual: 19/10/2021

Study start date

Actual: 01/02/2022

Date of final study report

Planned: 31/10/2025

Sources of funding

Other

More details on funding

Funded by European Centre for Disease Prevention and Control

Study protocol

Core protocol for ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection at primary care level

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable